



January 10, 2017

FOR IMMEDIATE RELEASE

Company name: U M N P h a r m a I n c .
Representative: Chairman and CEO Tatsuyoshi Hirano
Securities code: 4585
Contact person: CFO Hiroyuki Hashimoto
(T E L) + 8 1 - 4 5 - 5 9 5 - 9 8 4 0

Notice Received from Astellas for its Exercise of Termination Right of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501)

UMN Pharma Inc. (“the Company”) has received notice from Astellas Pharma Inc. (TSE:4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka, “Astellas”) to exercise termination right on the agreement, reached on September 10, 2010, to co-develop ASP7374 (“UMN-0502”, recombinant influenza HA vaccine for the prevention of seasonal influenza) and ASP7373 (“UMN-0501”, recombinant influenza HA vaccine (H5N1) for the prevention of pandemic influenza).

Astellas would commence the procedure to withdraw the application for marketing approval of recombinant influenza HA vaccine ASP7374(UMN-0502) for the prevention of seasonal influenza, which was submitted to the Ministry of Health, Labour and Welfare in May, 2014. Concurrently, the Company and Astellas will take the procedure for the termination of the agreement, and at the completion of the process, restitution of all the rights granted to Astellas subject to the agreement will be returned to the Company.

As for the background of this release and the Company’s alternative business plan, please refer to another release disclosed today, “Background of Termination Notice from Astellas of the agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501) and the Alternative Business Plan “.

【Impacts on the Company’s financial forecasts and mid-term business plan】

The impacts of this release on the Company’s financial forecasts and mid-term business plan cannot reasonably be assessed at this point. The related information will be provided as soon as it becomes available.